Fosravuconazole

Drug Profile

Fosravuconazole

Alternative Names: BFE-1224; BMS-379224; E-1224; Ravuconazole prodrug - Eisai

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Drugs for Neglected Diseases Initiative Foundation; Eisai Co Ltd; Seren Pharmaceuticals
  • Class Antifungals; Antiprotozoals; Fluorobenzenes; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Onychomycosis
  • Phase II Chagas disease
  • Discontinued Mycoses

Most Recent Events

  • 10 Sep 2015 The Drugs for Neglected Diseases initiative plans a clinical study for Eumycetoma
  • 10 Sep 2015 Eisai and The Drugs for Neglected Diseases initiative collaborate for development of fosravuconazole for the treatment of Eumycetoma
  • 31 Oct 2014 Phase-III clinical trials in Onychomycosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top